This product is a CRISPR/Cas9-edited polyclonal population of K-562 cells with targeted disruption of the DIDO1 gene. The polyclonal nature ensures a diverse range of editing events, providing a robust loss-of-function model without clonal bias. This knockout tool allows researchers to interrogate DIDO1 function across a mixed population, reflecting heterogeneous gene-editing outcomes that approximate physiological genetic variability. The product is suitable for functional studies requiring stable gene ablation in a pooled format.
The host cell line, K-562, is a widely used human chronic myelogenous leukemia (CML) cell line with erythroleukemic characteristics. Originally derived from the pleural effusion of a 53-year-old female in blast crisis, K-562 cells harbor the Philadelphia chromosome, producing the BCR-ABL fusion oncoprotein. This cell line serves as a fundamental model for studying CML pathogenesis, erythroid differentiation, and drug responses, offering a versatile platform for apoptosis and centrosome research.
DIDO1 is a nuclear protein that functions as a key regulator of apoptosis and centrosome integrity. Upon DNA damage or p53 activation, DIDO1 translocates to mitochondria, where it promotes cytochrome c release and downstream caspase-9 and caspase-3 activation, engaging the intrinsic apoptotic pathway. DIDO1 interacts with BCL2 family members such as BAX and BCL2, triggering mitochondrial outer membrane permeabilization. Additionally, DIDO1 localizes to centrosomes and regulates centrosome duplication by interacting with CPAP and PLK4, contributing to genomic stability. Its involvement in transcriptional regulation and RNA splicing further expands its functional reach.
In K-562 cells, DIDO1 knockout disrupts these critical pathways, rendering this polyclonal model invaluable for leukemia research. Loss of DIDO1 impairs apoptotic signaling and alters centrosome dynamics, potentially enhancing chemoresistance or promoting aneuploidy. The model enables studies on how chronic myeloid leukemia cells evade apoptosis and maintain genomic instability, offering insights into disease progression and therapeutic vulnerabilities. The pooled polyclonal format mimics heterogeneous tumor cell populations, providing a realistic system for drug screening and functional genomics.
Researchers can employ this DIDO1 knockout model in various applications. Western blotting and RT-qPCR validate gene disruption and downstream signaling, while Annexin V/PI flow cytometry and caspase activity assays quantify apoptosis. Immunofluorescence for centrosomal markers, cytochrome c release assays, and cell cycle analysis allow mechanistic dissection. Colony formation and MTS drug sensitivity assays evaluate oncogenic potential and therapeutic responses. Stem cell differentiation studies benefit from probing DIDO1??s role in pluripotency maintenance. For comprehensive technical support, please contact Ascent Research.
